Anand Patel, MD
Emergency Medicine · San Diego, CANPI 1225070345
Payments from drug & device makers
Across 10 payments — averaging $1514.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mediview XR, Inc.$15K
- Johnson & Johnson$149
What the payments were for
- Consulting fees$15,00099%
- Food & beverage$1491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mediview XR, Inc. | 2 | $15,000 |
| Johnson & Johnson | 8 | $149 |
How this compares
$15,149 in reported general payments places this provider in the 95th percentile of 6,006 emergency medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 315 | $224,172 |
| XareltoRivaroxaban | 91 | $62,540 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $48,442 |
| OzempicSemaglutide | 34 | $46,116 |
| TrulicityDulaglutide | 30 | $44,160 |
| XifaxanRifaximin | 13 | $43,749 |
| MyrbetriqMirabegron | 99 | $34,536 |
| CreonLipase/Protease/Amylase | 20 | $29,080 |
| JanuviaSitagliptin Phosphate | 36 | $28,716 |
| Invega SustennaPaliperidone Palmitate | 12 | $26,705 |
| JardianceEmpagliflozin | 28 | $26,508 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $18,101 |
| EntrestoSacubitril/Valsartan | 23 | $15,540 |
| RytaryCarbidopa/Levodopa | 18 | $13,248 |
| HorizantGabapentin Enacarbil | 26 | $12,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invega Sustenna | $149 | $89,244103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,006 emergency medicine providers in California.
Other emergency medicine in San Diego
- Justin SeltzerSan Diego$481K
- Vaishal ToliaSan Diego$245K
- Paul PearigenSan Diego$208K
- Christopher CoyneSan Diego$171K
- Elizabeth KaufmanSan Diego$154K
- Andrew LafreeSan Diego$96K
- Jeffrey OvercashChula Vista$31.8M
- Todd SimmonsEscondido$19.9M
- Michael WatersChula Vista$13.3M
- Barry HellerLong Beach$11.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.